3-Aminopiperidine-2,6-Dione Hydrochloride CAS 24666-56-6;2686-86-4 Purity > 99.0% Lenalidomide Intermediate Hoobkas
Ruifu Chemical yog cov chaw tsim khoom ntawm 3-Aminopiperidine-2,6-Dione Hydrochloride (CAS: 24666-56-6; 2686-86-4) nrog cov khoom zoo, nruab nrab ntawm Pomalidomide (CAS: 19171-19-8).Ruifu Chemical tuaj yeem muab kev xa khoom thoob ntiaj teb, tus nqi sib tw, kev pabcuam zoo heev, me me thiab ntau ntau muaj.Yuav 3-Aminopiperidine-2,6-Dione Hydrochloride, Please contact: alvin@ruifuchem.com
| Tshuaj npe | 3-Aminopiperidine-2,6-Dione Hydrochloride |
| Synonyms | 3-Aminopiperidine-2,6-Dione HCl;3-Amino-2,6-Piperidinedione Hydrochloride;2,6-Dioxopiperidine-3-Ammonium Chloride |
| CAS Nr | 24666-56-6 |
| Related CAS | 2686-86-4;25181-50-4 ib |
| Tshuag xwm txheej | Nyob rau hauv Tshuag, ntau lawm Scale mus txog Tons |
| Molecular Formula | C5H9ClN2O2 |
| Molecular Luj | 164.59 Nws |
| Melting Point | 120 ℃ |
| COA & MSDS | Muaj |
| Keeb kwm | Shanghai, Suav |
| Hom | Ruifu Tshuaj |
| Yam khoom | Specifications |
| Qhov tshwm sim | Off-White Crystalline Powder |
| Purity / Analysis Method | > 99.0% (HPLC) |
| Moisture (KF) | <0.50% |
| Poob rau ziab | <0.50% |
| Residue ntawm Ignition | <0.20% |
| Tag nrho cov impurities | <1.00% |
| Infrared Spectrum | Raws li tus qauv |
| Test Standard | Enterprise Standard |
| Kev siv | Intermediate ntawm Lenalidomide (CAS: 191732-72-6) |
Pob: Lub raj mis, Aluminium ntawv ci hnab, 25kg / Cardboard Nruas, los yog raws li tus neeg yuav tsum tau muaj
Cia txias:Khaws rau hauv cov thawv ntim khoom ntawm qhov chaw txias thiab qhuav;Tiv thaiv los ntawm lub teeb thiab noo noo
3-Aminopiperidine-2,6-Dione Hydrochloride (CAS: 24666-56-6; 2686-86-4) yog ib qho nruab nrab rau kev npaj Lenalidomide (CAS: 191732-72-6).Lenalidomide yog ib hom tshuaj tua kab mob uas tsim los ntawm Asmeskas cov tuam txhab tshuaj lom neeg.Nws muaj ntau yam haujlwm xws li tshuaj tiv thaiv qog, tiv thaiv kab mob thiab tiv thaiv angiogenesis.Nws tuaj yeem inhibit qhov tso tawm ntawm cov kab mob inflammatory cytokines, thiab nce qhov tso tawm ntawm peripheral ntshav mononuclear anti-inflammatory cytokines.Nws tuaj yeem cuam tshuam kev loj hlob ntawm cov neeg mob ntau lub hlwb myeloma thiab MM1S cell.Ob qhov multicenter randomized ob qhov muag tsis pom kev placebo-tswj cov kev tshawb fawb soj ntsuam kev nyab xeeb thiab kho cov nyhuv ntawm lenalidomide uas yog siv rau ntau yam myeloma.Cov kev tshawb fawb soj ntsuam tsis ntev los no qhia tau hais tias lenalidomide tsis yog tsuas yog muaj kev kho mob ntawm kev kho MDS thiab MM, tab sis kuj kho myeloma, leukemia, metastatic lub raum cell carcinoma, cov qog nqaij hlav, idiopathic generalized amyloidosis thiab kab mob hauv cov pob txha pob txha fibrosis nrog cov pob txha mos.Thaum Lub Kaum Ob Hlis 2005, US Food and Drug Administration (FDA) tau pom zoo lenalidomide los siv rau hauv kev kho mob myelodysplastic syndrome (MDS).
